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Molecul ar Method
The blood group multiplex ligation-dependent probe amplification 
(MLPA) is a comprehensive assay, developed for genotyping 
the majority of clinically relevant blood group antigens in both 
patients and donors. The MLPA is an easy method to apply and 
only requires a thermal cycler and capillary electrophoresis 
equipment. Because the molecular basis of blood group antigens 
can be a single nucleotide polymorphism, an insertion/deletion 
polymorphism, or genetic recombination, a single assay such as 
the MLPA to facilitate these different types of genetic variation 
is a prerequisite in blood group typing. An MLPA assay allows 
the simultaneous detection of up to 50 polymorphisms in a 
single tube. The blood group MLPA currently consists of three 
separate probe pools targeting 104 different blood group alleles 
of 18 blood group systems. The assay is performed in a 96-well 
plate; therefore, a maximum of 32 genomic DNA samples can be 
processed simultaneously. Results are available within 24 hours, 
and software for analysis of the MLPA results is available free of 
charge. In addition to the analysis of genetic variation in blood 
group genes, a major advantage of the test is the ability to detect 
aberrations in gene copy numbers, which is especially useful for 
the determination of homo- or hemizygous status of RHD or 
other blood group genes and for detection of blood chimerism. 
A relatively large number of RH wild-type and mutation-specific 
probes are included in the assay, allowing an extensive analysis of 
RHD variants. In our reference lab in the Netherlands, the MLPA 
was validated to detect RH variants in patients, donors, and 
pregnant women. Furthermore, we have used the MLPA to provide 
comprehensive typing after blood transfusion of 52 blood group 
antigens simultaneously, in patients with red cell autoantibodies 
or patients with rare phenotypes. Immunohematology 
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Blood group genotyping using genomic DNA from 
both patients and donors is a widely accepted alternative to 
the traditionally used serologic methods to type for blood 
group antigens present on the surface of red blood cells.1 
The advantages of genotyping over serologic typing is that 
many antigens can be determined in just one test and typing 
is independent of recent blood transfusions or presence of 
autoantibodies. In addition, genotyping can be more reliable 
in detecting weakly expressed antigens or rare antigens for 
which a limited amount of antisera is present. Comprehensive 
blood group typing makes more extensive antigen matching 
between donor and patient possible, which is expected to 
reduce the incidence of red cell antibody formation, hence 
reducing the number of (delayed) hemolytic transfusion 
reactions and reducing the number of cases demanding 
complex serologic investigations. Because molecular methods 
are eminently suitable for large-scale and high-throughput 
analysis, genotyping is a well-suited method to achieve 
comprehensive matching.2 The multiplex ligation-dependent 
probe amplification (MLPA) assay has been developed in the 
Netherlands to detect RHD variants and RHD zygosity, as well 
as polymorphisms for 17 other blood group systems and those 
responsible for four human platelet antigens.3,4
The MLPA (www.MLPA.com) is a multiplex genotyping 
method able to detect both genetic variation and gene copy 
number variation by comparing a test sample with a genotyped 
reference sample.5 The assay uses unamplified genomic DNA 
as starting material. Probe pairs with polymerase chain 
reaction (PCR) primer tags, located immediately adjacent to 
each other, are hybridized to genomic DNA and subsequently 
ligated together. Only in cases of a complete match between 
probe and a single nucleotide polymorphism (SNP) allele 
will ligation take place; these products will be amplified in a 
subsequent PCR using fluorescently labeled primers. Each 
ligated probe will give rise to a PCR product of specific length 
ranging from 90 to 500 bp, allowing the analysis of up to 50 
target sequences simultaneously. PCR products are analyzed 
using capillary electrophoresis resulting in a peak pattern 
from which the phenotype and zygosity can be inferred. In 
case of a mismatch between probe and genomic DNA, no PCR 
product will be generated and the associated signal is missing 
from the peak pattern. Because the targeted SNPs within the 
RHD gene are too close together such that they are unable to 
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be analyzed within the same reaction mix, the blood group 
MLPA is divided  into three different pools (P401, P402, and 
P403), thus reducing the maximum number of samples in a 
96-well assay to 32. Each pool of probe mixes also includes 
10 control probe pairs targeting random sequences within the 
human genome that are used for data normalization; wild-
type probe pairs specific to determine the copy number of 
blood group antigens, mutation-specific probe pairs that only 
detect the presence of a specific variant, and gender-specific 
probe pairs. In total, 47 probe pairs are RH-specific, 4 probe 
pairs target the human platelet antigens (HPA-1 and HPA-2), 
2 probe pairs target the X and Y gene, and 53 probe pairs are 
specific to determine antigens and variants of the MNS (M, N, 
S, s, U, Mur), LU (Lua/Lub, Aua/Aub), KEL (K/k, Jsa/Jsb, Kpa/
Kpb), LE (Lea-b- 59T), FY (Fya/Fyb, GATA, Fyx), JK (Jka/Jkb), 
DI (Dia/Dib), YT (Yta/Ytb), SC (Sc1/Sc2), DO (Doa/Dob, Gya, 
Hy, Joa), CO (Coa/Cob), LW (Lwa/Lwb), GE (Ge3, Ge4, Ge7-), 
CROM (Cra), KN (Kna/Knb), IN (Ina/Inb), and OK (Oka) blood 
group systems.6 Because the maximum number of 50 SNPs 
is not used for the third mix, probes can be easily added—for 
example, probes to detect Vel negativity7,8 or null alleles of the 
Kell blood group system.9
Procedure
The MLPA for blood groups can be performed using three 
separate kits (MLPA SALSA P401-A1, P402-A1, P403-A1, 
MRC-Holland, Amsterdam, the Netherlands) or (order@
MLPA.com) as separate products in four pack sizes: 25, 34, 
50, or 100 reactions in conjunction with MLPA reagents 
EK1. The input material for an MLPA is genomic DNA. Most 
DNA isolation procedures will produce sufficiently purified 
DNA, although sometimes the DNA quality influences the 
peak pattern and an additional column purification step is 
necessary to improve assay performance. The amount of 
DNA needed for one MLPA assay is 5 µL of a 10 ng/µL DNA 
dilution; hence, for all three blood group MLPA pools, 150 ng of 
genomic DNA is sufficient. The MLPA is a one-tube assay that 
can be divided into five steps. The first step is the overnight 
hybridization (16 hours) of denatured genomic DNA to three 
separate mixes with probe pairs (Fig. 1). A probe pair consists 
of a SNP-specific probe and a gene-specific probe each with a 
PCR primer tag, which hybridize immediately adjacent to each 
other. The minimal genomic hybridizing part of a probe is 20 
nucleotides; thus, the distance between SNPs to be analyzed 
in the same probe mix should be at least 40 nucleotides. In 
the second step, the hybridized probe pairs are ligated (Fig. 1). 
Ligation requires a perfect match with a SNP allele, generating 
a product with PCR primer tags on both sites. In the third 
step, a PCR is performed on the ligated probe pairs using a 
fluorescent-labeled primer pair (Fig. 1). Since mismatch 
between probe and genomic DNA will not generate a ligated 
product, no amplification will take place during PCR. The 
fourth step is size separation of PCR products using capillary 
electrophoresis (Fig. 1). From the resulting peak pattern, the 
absence and presence of certain lengths of amplified products 
can be defined and the associated phenotype predicted. The 
final step is the comparison of the obtained peak pattern with 
a reference sample using either free (Coffalyser software, 
MLPA assay for blood group genotyping
Fig. 1. Multiplex ligation-dependent probe amplification (MLPA) 
procedure in five steps. (1) A mix containing up to 50 probe pairs 
is hybridized overnight to produce denatured genomic DNA. Every 
probe pair has an X and Y tag with polymerase chain reaction (PCR) 
primer sequence. (2) Ligation of perfectly hybridized probes. In case 
of a mismatch, no ligation takes place. (3) PCR amplification of the 
ligated product with primer X and Y, resulting in a series of products 
of unique length. (4) The PCR products are separated by capillary 
electrophoresis, resulting in a peak pattern. (5) Data are analyzed 
by comparing the peaks of a test sample with those of a reference 
sample. Analysis software will produce a table with peak ratios 
compared with a reference sample; from these results, the genotype 
and the associated phenotype can be inferred manually.
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www.MLPA.com) or commercially available (GeneMarker, 
SoftGenetic, LLC, State College, PA) software. The software 
generates a peak ratio of a sample when compared with a 
known reference sample. The total pattern of absent and 
present peaks and aberrant copy numbers (zygosity) allows 
the manual determination of the blood group antigens and the 
blood group variants. Software translating the genotype to a 
phenotype is not yet available, but will become available from 
MRC-Holland in the future. The MLPA takes approximately 
24 hours, including 16 hours of hybridization and 1.5 hours of 
hands-on time.
Performance
The MLPA has been validated using both serologic typing 
and sequencing of polymorphisms of 253 samples. In 4018 
(99.5%) of the 4038 serologic typing results, the phenotypes 
predicted by the blood group MLPA were in concordance 
with serologic typing.4 Twenty discordant results were found 
to be attributable to false-positive serologic results (n = 2), 
false-negative serologic results (n = 1), inability of routine 
serologic typing to detect variant antigens (n = 14), or false-
positive prediction from the MLPA caused by the presence of 
a null allele (n = 3). Although some probes for null mutations 
are included (Rh, Lewis, Duffy, U–, Dombrock, and Gerbich), 
null mutations not included in the assay will result in false-
positive predictions—clinically unimportant for donor 
typing, although essential for patients. Compared with 
other genotyping methods (PreciseType™ HEA Molecular 
BeadChip™ Test, Bioarray Solutions, Immucor, Warren, NJ; 
BloodChip, Progenika Biopharma S.A., Grifols, Bizkaia, Spain; 
and Sanger sequencing), which can be performed within a 
day, MLPA is rather slow, taking almost 24 hours to obtain 
results  because of the overnight hybridization step. The assay 
is therefore unsuitable if time is limited. A major advantage of 
the MLPA, however, is its ability to detect aberrations in gene 
copy numbers, which cannot be achieved with the commonly 
used commercially available blood group antigen genotyping 
assays.
Although the test is a one-tube protocol, reducing the 
possibility of sample switching, the assay and data analysis 
have not yet been automated. Software is available for 
comparison of a test sample to a reference sample to produce 
peak ratios, and will be extended with software to predict 
a phenotype from the determined genotype. Automated 
uploading of the test result to the laboratory information 
system will follow the final version of the genotype prediction 
software, but is not yet available. The method is not technically 
complicated and is relatively simple to implement, as only a 
thermal cycler and capillary electrophoresis equipment are 
needed. This equipment is available in most molecular labs. 
The test is relatively inexpensive (approximately $11 to $17 
per sample per well, or about $45 for a complete blood group 
typing excluding the cost for the DNA isolation). The three 
MLPA pools combined can predict 51 different blood group 
antigens4 (excluding RHD variants and HPA-1 and HPA-2); 
thus, the costs per antigen per individual are approximately 
$0.87. The first two probe mixes contain the maximum number 
of probe pairs, but the third mix with 35 probe pairs can still 
be expanded. The probe mixes are not CE-marked, although 
the MLPA reagents and Coffalyser software are CE-marked for 
the European market. In addition to the ready-to-use probe 
mixes, probes can also be custom-designed, allowing the 
development of your own content.10 A protocol is available at 
the MRC-Holland website (www.MLPA.com). Although the 
MLPA is unsuitable for large-scale, high-throughput typing 
of donor populations, it is powerful for genotyping of patients, 
especially for RHD variants and zygosity typing. The assay 
discriminates weak D types 1, 2, and 3 (which are regarded as 
D+) from other weak D types and RHD variants.11,12 Recently, 
the blood group MLPA was used to determine D variants in 30 
Chinese individuals with weak or partial RHD expression.13 In 
24 cases (80%), a conclusive result was obtained by MLPA. In 
six cases, additional sequencing was needed, resulting in four 
novel alleles and two very rare known alleles (weak D type 17 
and weak D 101A>G). Although the MLPA recognizes most 
clinically significant variants, rare alleles are not detected and 
sequencing is necessary to find the mutation within RHD. 
Furthermore, that study showed the advantages of MLPA 
compared with the hybrid Rhesus box analysis to determine 
RHD zygosity. In our lab (Sanquin Blood Supply, Amsterdam, 
the Netherlands), every week, about 500 D– pregnant women 
are genotyped using RHD typing of cell-free fetal DNA isolated 
from maternal plasma. About 1 percent of these women 
produce a positive result because of a genetic variation in the 
maternal RHD. Currently, in most of these women, an RHD 
variant is detected by MLPA, although in 34 out of 277 cases 
(12%), the presence of RHD could be determined even when 
no mutation was detected by MLPA. Additional sequencing 
of the RHD gene was necessary to solve the underlying 
mutation responsible for the D– phenotype.
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